HomeCompareCMVLF vs BTI

CMVLF vs BTI: Dividend Comparison 2026

CMVLF yields 64.94% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CMVLF wins by $789.7K in total portfolio value
10 years
CMVLF
CMVLF
● Live price
64.94%
Share price
$3.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$827.5K
Annual income
$205,354.23
Full CMVLF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — CMVLF vs BTI

📍 CMVLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMVLFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMVLF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMVLF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMVLF
Annual income on $10K today (after 15% tax)
$5,519.48/yr
After 10yr DRIP, annual income (after tax)
$174,551.10/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, CMVLF beats the other by $172,182.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMVLF + BTI for your $10,000?

CMVLF: 50%BTI: 50%
100% BTI50/50100% CMVLF
Portfolio after 10yr
$432.6K
Annual income
$104,070.44/yr
Blended yield
24.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

CMVLF
Analyst Ratings
7
Buy
2
Hold
1
Sell
Consensus: Buy
Altman Z
-0.9
Piotroski
2/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMVLF buys
0
BTI buys
0
No recent congressional trades found for CMVLF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMVLFBTI
Forward yield64.94%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$827.5K$37.7K
Annual income after 10y$205,354.23$2,786.64
Total dividends collected$696.1K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: CMVLF vs BTI ($10,000, DRIP)

YearCMVLF PortfolioCMVLF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$17,194$6,493.51$11,299$598.92+$5.9KCMVLF
2$28,831$10,434.22$12,794$703.91+$16.0KCMVLF
3$47,202$16,352.17$14,518$829.07+$32.7KCMVLF
4$75,526$25,019.87$16,513$978.64+$59.0KCMVLF
5$118,227$37,414.37$18,827$1,157.84+$99.4KCMVLF
6$181,239$54,736.40$21,518$1,373.12+$159.7KCMVLF
7$272,346$78,420.28$24,657$1,632.46+$247.7KCMVLF
8$401,542$110,132.11$28,329$1,945.74+$373.2KCMVLF
9$581,404$151,754.11$32,637$2,325.33+$548.8KCMVLF
10$827,457$205,354.23$37,708$2,786.64+$789.7KCMVLF

CMVLF vs BTI: Complete Analysis 2026

CMVLFStock

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Full CMVLF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this CMVLF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMVLF vs SCHDCMVLF vs JEPICMVLF vs OCMVLF vs KOCMVLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.